scispace - formally typeset
Open AccessJournal ArticleDOI

Status Report on COVID-19 Vaccines Development

TLDR
In this article, the authors summarized novel and traditional approaches for COVID-19 vaccine development including inactivated, attenuated, nucleic acid, vector and protein based, and showed comparative immunogenicity profiles of various vaccines in clinical phases.
Abstract
The emergence of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has affected lives of billions of individuals, globally. There is an urgent need to develop interventions including vaccines to control the ongoing pandemic. Development of tools for fast-tracked testing including small and large animal models for vaccine efficacy analysis, assays for immunogenicity assessment, critical reagents, international biological standards, and data sharing allowed accelerated development of vaccines. More than 300 vaccines are under development and 9 of them are approved for emergency use in various countries, with impressive efficacy ranging from 50 to 95%. Recently, several new SARS-CoV-2 variants have emerged and are circulating globally, and preliminary findings imply that some of them may escape immune responses against previous variants and diminish efficacy of current vaccines. Most of these variants acquired new mutations in their surface protein (Spike) which is the antigen in most of the approved/under development vaccines. In this review, we summarize novel and traditional approaches for COVID-19 vaccine development including inactivated, attenuated, nucleic acid, vector and protein based. Critical assessment of humoral and cell-mediated immune responses induced by vaccines has shown comparative immunogenicity profiles of various vaccines in clinical phases. Recent reports confirmed that some currently available vaccines provide partial to complete protection against emerging SARS-CoV-2 variants. If more mutated variants emerge, current vaccines might need to be updated accordingly either by developing vaccines matching the circulating strain or designing multivalent vaccines to extend the breadth.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Global COVID-19 Vaccine Acceptance: A Systematic Review of Associated Social and Behavioral Factors

TL;DR: The analysis shows that there are global variations in vaccine acceptance among different populations, and the reasons behind vaccine hesitancy and acceptance were similar across the board.
Journal ArticleDOI

Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection

TL;DR: In this paper, the authors review the currently available evidence on tenofovir's efficacy against SARS-CoV-2 infection and conclude that it is not the only antiviral medication approved for COVID-19.
Journal ArticleDOI

Addressing Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following COVID-19 Vaccination: A Mini-Review of Practical Strategies

TL;DR: In this paper, the authors provide a comprehensive overview of vaccine-induced immune thrombotic thrombinopathy (VITT) in COVID-19 vaccine immunization.
Journal ArticleDOI

An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines

TL;DR: This study has a review on inactivated SARS‐CoV‐2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features.
References
More filters
Journal ArticleDOI

A Novel Coronavirus from Patients with Pneumonia in China, 2019.

TL;DR: Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily, which is the seventh member of the family of coronaviruses that infect humans.
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Related Papers (5)
Trending Questions (1)
What are some of the steps that were skipped in the development of the COVID-19 vaccines?

The paper does not mention any steps that were skipped in the development of the COVID-19 vaccines.